The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …

Simple Summary This article discusses the use of peptide receptor radionuclide therapy
(PRRT) as a key treatment method for advanced, unresectable neuroendocrine tumors. It …

Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment
for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs …

Abstract Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted
therapy which is performed by using a small peptide (somatostatin analogue—SSA) that is …

Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of
neuroendocrine tumors. Peptide-receptor radionuclide therapy (PRRT) in neuroendocrine …

The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled
somatostatin analogs represent a milestone in the development of theranostic compounds …

Peptide receptor scintigraphy in humans started with the in vivo demonstration of
somatostatin receptor-positive tumors in patients using a radioiodinated somatostatin …

The diagnosis and subsequent therapy of neuroendocrine neoplasms (NENs) have long
relied on somatostatin receptor (SSTR) expression. The field of theranostics now uses …

Theranostics of neuroendocrine neoplasms (NENs) based on molecular imaging using
receptor positron emission tomography/computed tomography (PET/CT) with 68Ga-labeled …

To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT)
of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of …